

## Type 2 Diabetes in adults (medicines update) Committee meeting 5

**Date:** 16/10/2023

**Location:** Virtual

**Minutes:** Final

<b>Committee members present:</b>		
Waqar Shah (Chair)		Present for notes 1 – 9
Chirag Bakhai		Present until partway through item 7
Catherine Bewsey		Present for notes 1 – 9
Mimi Chen		Present for notes 1 – 9
Hussain Contractor		Present for notes 1 – 9
Dan Cuthbertson (Topic Adviser)		Present until partway through item 7
Hugh Gallagher		Present for notes 1 – 9
Natasha Jacques		Present for notes 1 – 9
Sallianne Kavanagh		Present until partway through item 7
Sharon McCarthy		Present until partway through item 7
Soon Song		Present for notes 1 – 9
Annette Swinkels		Present for notes 1 – 9
John Turner		Present for notes 1 – 9

<b>In attendance:</b>		
Astrid Aregui	Senior Medical Editor	Present for notes 1 – 9
Jackie Durkin	Administrator	Present for item 1
Linyun Fou	Technical Analyst	Present for notes 7 - 9
Rupert Franklin	Senior Guideline Commissioning Manager	Present for notes 1 – 8
Sarah Glover	Information Specialist	Present from partway through item 6
James Hawkins	Senior Health Economist	Present for notes 1 – 8
Sarah Matthews	Technical Analyst	Present for notes 1-6
Caroline Mulvihill	Technical Adviser, Guideline	Present for notes 1 – 8

	Lead	
Sade Naku	Health Economist	Present for notes 1 – 8
Adam O’Keefe	Project Manager	Present for notes 1 – 8
Nancy Pursey	Trainee Technical Analyst	Present for notes 1 – 8
Muksitur Rahman	Health Economist	Present for notes 1 – 8
Emily Terrazas-Cruz	Senior Research Fellow	Present for notes 1 – 8
Philip Williams	Finance Analyst	Present for notes 1 – 8
George Wood	Senior Technical Analyst	Present for notes 1 – 8

<b>External in attendance:</b>	
Beatrice Downing, NICE Guidelines Technical Support Unit, University of Bristol	Present for notes 1 – 8
Hugo Pedder, NICE Guidelines Technical Support Unit, University of Bristol	Present for notes 1 – 8

<b>Apologies:</b>	
Neel Basudev	Committee member
Sithembile Thokozile Chinaire	Committee member
Anne Dornhorst	Committee member
Gosia Wamil	Committee member

<b>1. Welcome, introductions and apologies</b>				
<p>The Chair welcomed the Committee members and attendees, including colleagues from the NICE Guidelines Technical Support Unit at University of Bristol to the fifth meeting on Type 2 Diabetes in adults (medicines update). The Chair informed the Committee that apologies had been received. These are noted above.</p> <p>The Chair welcomed newly appointed committee member Hussain Contractor to their first meeting.</p>				
<b>2. Confirmation of matter under discussion, and declarations of interest</b>				
<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initial and subsequent treatment of type 2 diabetes.</p> <p>The Chair asked committee members to verbally declare any new interests, these are noted below:</p>				
Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken

Soon Song	Committee member, Consultant Diabetologist	Presented the abstract entitled 'Metabolic emergencies in type 1 and type 2 diabetes presenting to a hospital emergency department: frequencies, co-morbidities and mortality outcomes' at the EASD conference in Hamburg October 2023.	Direct, non-financial professional and personal	Declare and participate. Not specific to the scope of the guideline update
<p>Dan Cuthbertson, Topic Adviser, reminded those present of an interest previously declared at meeting 3 of publication of a paper which used data from TriNetX, which is ongoing.</p> <p>The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.</p>				
<b>3. Minutes of previous meeting</b>				
The minutes of the previous meeting were accepted as a true and accurate record.				
<b>4. Health economics</b>				
The Chair introduced Muksit Rahman, Health Economist (MR) who discussed elements of the Health economic modelling with the committee, including model outcomes and Treatment-related adverse events to be modelled.				
<b>5. and 6. Review Question 1.1 For different population subgroups, which individual and/or combinations of pharmacological therapies are most clinically and cost effective as initial treatment for the management of type 2 diabetes?</b>				
The Chair welcome Beatrice Downing and Hugo Pedder from NICE's Guidelines Technical Support Unit at University of Bristol, who presented the committee with preliminary outputs from the Network Meta-Analyses being produced in support of Review Question 1.1. The committee discussed the evidence presented to them though decided not to draft any recommendations at this stage. The committee also discussed health inequalities considerations raised. BD and HP also sought the committee's input on modelling of the NMA.				
<b>7. and 8. Review Question 1.2 Which pharmacological therapies are most clinically and cost effective for the management of type 2 diabetes when current treatment has not given adequate response?</b>				
<p><b>- Heart failure and chronic kidney disease outcomes</b></p> <p>The chair introduced Linyun Fou and Nancy Pursey, Technical Analysts, who presented clinical evidence identified in support of Review Question 1.2 for Heart</p>				

failure and chronic kidney disease outcomes. Sarah Matthews was scheduled to present but was unable to attend this item. MR then presented the health economic evidence informing the review question.

Due to time constraints the committee agreed to discuss the evidence presented to them and draft any recommendations at the next meeting.

### **9. AOB**

Adam O'Keefe, Project Manager (AO) outlined next steps before the Chair thanked participants and closed the meeting.

**Date of next meeting:** Guideline Committee Meeting 6: 14 November 2023

**Location of next meeting:** Virtual